$16.96
0.64% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
CH1242303498
Symbol
OCS
Sector
Industry

Oculis Stock price

$16.96
+0.80 4.95% 1M
+5.26 44.96% 6M
+5.73 51.02% YTD
+5.66 50.09% 1Y
+6.80 66.93% 3Y
+6.80 66.93% 5Y
+6.80 66.93% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.11 0.64%
ISIN
CH1242303498
Symbol
OCS
Sector
Industry

Key metrics

Market capitalization $691.04m
Enterprise Value $567.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 6.30
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-78.03m
Free Cash Flow (TTM) Free Cash Flow $-57.04m
Cash position $125.03m
EPS (TTM) EPS $-2.01
P/E forward negative
P/S forward 684.05
EV/Sales forward 561.74
Short interest 0.07%
Show more

Is Oculis a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Oculis Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Oculis forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Oculis forecast:

Buy
100%

Financial data from Oculis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.40 0.40
-
-
-0.40 -0.40
-
-
- Selling and Administrative Expenses 23 23
-
-
- Research and Development Expense 54 54
-
-
-78 -78
-
-
- Depreciation and Amortization 0.40 0.40
-
-
EBIT (Operating Income) EBIT -78 -78
6,995% 6,995%
-
Net Profit -79 -79
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Oculis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oculis Stock News

Neutral
GlobeNewsWire
22 days ago
ZUG, Switzerland, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Neutral
GlobeNewsWire
30 days ago
ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
Neutral
GlobeNewsWire
about one month ago
ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the Company.
More Oculis News

Company Profile

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Riad Sherif
Employees 36
Founded 2016
Website oculis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today